Edition:
United Kingdom

Merus NV (MRUS.OQ)

MRUS.OQ on NASDAQ Stock Exchange Global Market

19.04USD
23 May 2018
Change (% chg)

$0.54 (+2.92%)
Prev Close
$18.50
Open
$18.60
Day's High
$19.52
Day's Low
$18.60
Volume
9,633
Avg. Vol
10,379
52-wk High
$22.00
52-wk Low
$13.33

Latest Key Developments (Source: Significant Developments)

Merus Files Prospectus Relates To Proposed Resale Or Other Disposition Of Co's Shares By Selling Shareholders
Tuesday, 15 May 2018 

May 15 (Reuters) - Merus NV ::MERUS NV FILES PROSPECTUS RELATES TO PROPOSED RESALE OR OTHER DISPOSITION OF UP TO 3.1 MILLION OF CO'S COMMON SHARES BY SELLING SHAREHOLDERS - SEC FILING.  Full Article

Merus And Simcere Announce Strategic Collaboration On Multiple Bispecific Antibodies
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Simcere Pharmaceutical Group ::MERUS AND SIMCERE ANNOUNCE STRATEGIC COLLABORATION ON MULTIPLE BISPECIFIC ANTIBODIES.MERUS - AGREED TO GRANT SIMCERE EXCLUSIVE LICENSE TO DEVELOP & COMMERCIALIZE IN CHINA 3 BISPECIFIC ANTIBODIES USING CO'S BICLONICS TECHNOLOGY PLATFORM.MERUS NV- CO TO BE ELIGIBLE TO GET UPFRONT & MILESTONE PAYMENTS CONTINGENT UPON SIMCERE ACHIEVING CERTAIN SPECIFIED DEVELOPMENT & COMMERCIAL GOALS.MERUS NV - MERUS WILL BE ELIGIBLE TO RECEIVE TIERED ROYALTY PAYMENTS ON SALES OF ANY PRODUCTS RESULTING FROM COLLABORATION IN CHINA FROM SIMCERE.MERUS NV - SIMCERE WILL BE ELIGIBLE TO RECEIVE TIERED ROYALTY PAYMENTS ON SALES OUTSIDE OF CHINA FROM MERUS.MERUS NV - ADDITIONAL FINANCIAL DETAILS WERE NOT DISCLOSED UNDER COLLABORATION WITH SIMCERE.  Full Article

Merus Nv Q3 Loss Per Share Eur 0.81
Thursday, 30 Nov 2017 

Merus Nv ::MERUS ANNOUNCES THIRD QUARTER 2017 FINANCIAL RESULTS AND CLINICAL HIGHLIGHTS.Q3 LOSS PER SHARE EUR 0.81.Q3 REVENUE EUR 3.5 MILLION VERSUS EUR 1.2 MILLION.Q3 REVENUE VIEW EUR 2.2 MILLION -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW EUR -0.58 -- THOMSON REUTERS I/B/E/S.- ‍EXPECTS CURRENT CASH AND CASH EQUIVALENTS BALANCE TO BE SUFFICIENT TO FUND RESEARCH AND DEVELOPMENT PROGRAMS AND OPERATIONS WELL INTO 2019​.  Full Article

Aglaia Oncology Fund B.V. reports 6.9 percent passive stake in Merus Nv as of December 31, 2016
Friday, 10 Feb 2017 

Aglaia Oncology Fund B.V. :Aglaia Oncology Fund B.V. Reports a 6.9 percent passive stake in Merus Nv as of December 31, 2016 - SEC filing.  Full Article

Merus NV Q2 loss per share EUR 0.40
Monday, 8 Aug 2016 

Merus Nv : Q2 loss per share eur 0.40 . Q2 earnings per share view eur -0.49 -- Thomson Reuters I/B/E/S . Merus announces second quarter 2016 financial results and reviews recent clinical progress and corporate developments .Q2 revenue eur 1.1 million versus eur 1.2 million.  Full Article

Merus announces Q1 loss per share EUR 0.63
Tuesday, 12 Jul 2016 

Merus NV : Merus announces first quarter 2016 financial results and highlights recent clinical progress and corporate developments . Q1 loss per share EUR 0.63 .Q1 revenue eur 800,000 versus EUR 100,000.  Full Article

Pfizer says takes 7.1 pct passive stake in Merus NV
Monday, 6 Jun 2016 

Pfizer:Pfizer Says Takes 7.1 Pct Passive Stake In Merus NV Sec filing.  Full Article

BRIEF-Merus Q4 Loss Per Share EUR 0.73

* MERUS ANNOUNCES RECENT CORPORATE DEVELOPMENTS AND FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2017